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The performance oftheLungImaging FluorescenceEndoscope (LIFE) system was compared
with conventional bronchoscopy in 158 patients: 68 patients with invasive cancer, 42 patients
with abnormal sputum cytology findings (12 early cancer and 26 dysplasia), 17 cases with
resected lung cancer and 31 smokers with symptoms. The respective results of conventional
bronchoscopy and LIFE for detection of dysplasia were; sensitivity 52% and 90% (biopsy
basis), 62% and 92% (patient basis). Fluorescence bronchoscopy may be an important
adjunct to conventional bronchoscopy to improve the localization of subtle lesions of
bronchus.
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INTRODUCTION
The increasing numbers of lung cancer deaths are
mainly due to the detection of the disease at a late
stage. Prevention and early detection are essential to
decrease the death rate. When roentgenologically
occult lung cancer is detected by sputum cytology,
the only tool to localize the lesion is endoscopy.
However carcinoma in situ can be difficult to
identify by conventional white light bronchoscopy
alone [1]. Also, the endoscopic apperance of dys-
plasia is so subtle that even experienced bronchos-
copists sometimes fail to localize the lesions. To
solve this problem, fluorescence diagnosis was
applied to endoscopic imaging by Profio [2]. Kato
et al. began a clinical trial using fluorescence
bronchoscopy, employing a tumor-specific photo-
sensitizer as a sensitive and accurate method to
detect central type early lung cancer in 1980 [3-5].
Another approach has been made by Palcic and
Lamwho noticed the difference ofautofluorescence
between normal and tumor tissue. Using a high
quality CCD and special algorithm, they developed
the LIFE system [6,7]. As previously reported [8,9],
Corresponding author. Tel.: -+-81 3 3342 6111. Ext. 5071. Fax: +81 3 3349 0326.
8586 N. IKEDA et al.
this diagnostic procedure is helpful to detect subtle
lesions in the bronchus which can hardly be detected
by conventional bronchoscopy.
In this study, the authors will determine if
fluorescence bronchoscopy using the LIFE system
could improve the diagnostic rate of bronchial-
lesions, especially early cancer and dysplastic
lesions, compared with conventionalbronchoscopy.
MATERIALS AND METHODS
A total of 158 subjects were studied from June 1997
to May 1998 in Tokyo Medical University Hospital
and 262 sites were biopsied. The criteria for
enrollment in this study were as follows:
(1) Patients with cancer who were scheduled for
endoscopic examination before treatment (68
cases).
(2) Patients with abnormal sputum findings with
normal chest X-ray (42 cases).
(3) Patients who had undergone curative operation
of stage I lung cancer scheduled for endoscopy
for periodical follow-up (17 cases).
(4) Smokers with respiratory symptoms (31 cases).
The detailed characteristics of cases are shown in
Table I.
Conventional fiberoptic bronchoscopy (BF-20,
Olympus Optical Co., Tokyo, Japan) was first
performed and areas with abnormal findings (sus-
picious for cancer or dysplasia) were noted for
TABLE Characteristics of enrolled patients (158
cases)
Lung cancer 68 cases
endoscopically recognized/unrecognized 43/25
squamous cell carcinoma 30
adenocarcinoma 27
small cell carcinoma 4
large cell carcinoma 3
others 4




Follow up after operation 17 cases
Smokers with symptoms 31 cases
subsequent biopsy. The fluorescence examination
using LIFE (Xillix Technologies Corp, Richmond,
B.C., Canada) was then performed by the same
endoscopy team. The details of the LIFE system
have been reported previously [6,8]. Normal areas
show green autofluorescence when excited by blue
light but abnormal areas showed decreased auto-
fluorescence (Fig. 1), therefore, abnormal areas
were indicated by cold spots under fluorescence
imaging [7,10]. Any abnormal areas detected by
conventional bronchoscopy or by the LIFE device
were biopsied. Biopsy procedure was performed
under fluorescence imaging if the suspicious areas
could not be identified by conventional bronchos-
copy. Procedures were carried out under local
anesthesia and no additional sedation was neces-
sary. All biopsy specimens were interpreted in our
Department of Pathology and pathological diag-
nosis was the gold standard for the diagnosis of the
subjects as well as for the comparison of the
diagnostic accuracy of conventional bronchoscopy
and fluorescence diagnosis.
RESULTS
There were 112 men and 46 women with a mean age
of 64 (range 33-78). Of those, 132 (84%) were
current or former smokers with a mean smoking
index of840. The final pathological diagnosis of262
biopsy specimens were as follows: normal, inflam-
mation, metaplasia with no atypia in 135; dysplasia
in 72; early cancer in 12; and invasive cancer in 43.
Biopsy-based Analysis
Of the 262 biopsies, cancer was detected at 55 sites
(invasive cancer 43, early cancer 12) (Table II). Both
conventional bronchoscopy and the LIFE system
correctly diagnosed these lesions, but the extent and
margin of the lesions were more objectively
observed under fluorescence examination. Dyspla-
sia was detected in 72 sites, 19 sites were detected in
invasive cancer patients, 10 from early cancer, 36
sites from subjects with abnormal sputum findings,EARLY DETECTION BY LIFE 87
(A)
(B)
FIGURE Finding of normal bronchus (A) and the tumor (B) by fluorescence microscopy. Submucosal layer of normal
bronchus has strong autofluorescence excited at 420 nm, while tumor tissue has lost autofluorescence.
TABLE II Results of conventional bronchoscopy and the
LIFE system (Biopsy-based analysis, n 262)
LIFE negative LIFE positive
Invasive cancer (n 43)*
BF positive 43 (100%)
Early cancer (n 12)
BF positive 12 (100%)
Dysplasia (n 72)
BF negative 0 (0%) 35 (49%)
BF positive 7 (10%) 30 (42%)
Normal/Inflammation (n 135)
BF negative 60 (44%) 24 (18%)
BF positive 30 (22%) 21 (16%)
* Endoscopically unrecognized cases (25 cases) were excluded
from analysis.
5 from post-operative follow up, and 2 from
smokers with recurrent symptoms (Table III). The
sensitivity for dysplasia detection were 51% by
conventional bronchoscopy and 90% by the LIFE
TABLE III The prevalence of dysplasia
No. of cases No. of sites No. of cases with
multiple sites
Group (n 68) 12 (18%) 19 5 (7%)
Group II (n 42) 24 (57%)* 36 12 (29%)
Group III (n 17) 4 (24%) 5 (6%)
Group IV (n 31) 2 (7%) 2 0 (0%)
I, lung cancer; II, abnormal sputum cytology findings; III, follow
up after operation; IV, smokers with symptoms.
* 4 cases (10 sites) with early cancer.
system. The positive predictive value for dysplasia
and cancer was 64% by conventional bronchoscopy
and 73% by the LIFE system. In relation to
specificity, conventional bronchoscopy showed
62% and LIFE 66% (Table V).88 N. IKEDA et al.
Patient-based Analysis
Ofthe 158 patients, 68 invasive cancer patients were
enrolled in this study as a part of routine examina-
tion before treatment (Table IV). In 43 patients, a
definitive diagnosis of cancer was obtained by
bronchial biopsy and these lesions were observed
both by conventional and fluorescence bronchos-
copy. In the rest of 25 patients, the primary lesions
were located in the periphery of the lung, and could
not be observed endoscopically. These lesions were
diagnosed by transbronchial lung biopsy (TBLB) or
percutaneous needle cytology.A total of 19 dysplas-
tic lesions were detected in 68 invasive cancer cases,
one lesion was detected in 7 cases, 2 lesions in 4 and 4
lesions in case.
In 42 patients with abnormal sputum findings but
normal chest X-ray, central type early squamous cell
carcinoma was diagnosed in 12 patients and
dysplasia in 20 patients, but the origin of abnormal
sputum could not be identified in 10 cases. Dysplas-
tic lesions were detected in 4 out of 12 early cancer
cases; lesion in case, 2 lesions in 2 cases, and
5 lesions in case. A total of 36 dysplastic lesions
were detected in 20 dysplasia cases; lesion in 11
cases, 2 lesions in 6 cases, 3 lesions in case, 4 lesions
in case, and 6 lesions in case. Endoscopic
localization of the foci of 42 cases of abnormal
sputum cytology findings was successful in 24 cases
(57%, 12 early cancer and 12 dysplasia) by conven-
TABLE IV Results of conventional bronchoscopy and the
LIFE system (patient basis analysis, n 158)
LIFE negative LIFE positive
Invasive cancer (n 68)*
BF positive 43 (100%)
(TBLB, Needle biopsy 25)
Early cancer (n 12)
BF positive 12 (100%)
Dysplasia (n-- 26)
BF negative 0 (0%) 10 (38%)
BF positive 2 (8%) 14 (54%)
Normal/Inflammation (n-- 52)
BF negative 15 (29%) 8 (15%)
BF positive 12 (23%) 17 (33%)
Endoscopically unrecognized cases (25 cases) were excluded
from analysis.
tional bronchoscopy and in 32 cases (76%, 12 early
cancer and 20 dysplasia) by the LIFE system.
Among post-operative 17 cases, 4 cases (24%)
were revealed to have dysplastic lesions (1 lesion in 3
cases and 2 lesions in case), of which 2 cases were
diagnosed only by fluorescence examination. No
recurrent case was found in those patients. In the
group of smokers with continuous or recurrent
symptoms (31 cases), 2 cases (6%) were diagnosed
to have dysplasia. The prevalence of dysplasia is
shown in Table III. The results of patient basis
analysis are shown in Table IV.
Sensitivity ofdysplasia detection by patient based
analysis was 62% by conventional bronchoscopy
and 92% by the LIFE system. There were 52
patients who were pathologically diagnosed as
having chronic inflammation orfound to be normal.
Chronic inflammation was proved by findings of
biopsy specimens such as reserve cell hyperplasia,
thickened basement membrane, or lymphoid infil-
tration, etc. Specificity by patient based analysis was
44% for conventional bronchoscopy and 52% for
the LIFE system (Table V).
DISCUSSION
Sputum cytology examination is often the first
method to detect central type early cancer or
dysplasia, but even experienced bronchoscopists
sometimes fail to localize lesions. Such lesions are
too thin to show endoscopically visible mucosal
changes [1]. Dysplasia has been regarded as a
TABLE V Summary of clinical data
Biopsy basis Patient basis
BF LIFE BF LIFE
(%) (%) (%) (%)
Sensitivity
cancer and dysplasia 72 95 88 98
dysplasia 51 90 62 92
Positive predictive value 64 73 71 76
Specificity 62 66 44 52
Note: Cancer cases with invisible primary lesions were excluded
from analysis.EARLY DETECTION BY LIFE 89
precancerous state of central type early cancer
according to the concept of carcinogenesis as a
multistep process [11,12]. Dysplasia can be found in
patients with non-cancerous disease, therefore the
relationship between cancer and dysplasia is not
well confirmed. However, if dysplasia is a precan-
cerous stage, diagnosis ofdysplasiawould be helpful
for the prevention or early detection of lung cancer.
The bronchoscopic findings of dysplasia have not
been carefully studied. Thickening ofthe mucosa is a
common finding of dysplasia but such a finding is
also observed in inflamed airways. Lam and Palcic
noticed the lack of autofluorescence in the tumor
lesion and they amplified the difference of auto-
fluorescence between normal and tumor tissue for
clinical use. Using a high quality CCD, image
intensifier and special algorithm, the LIFE system
was developed [6-8]. As previously reported, the
diagnostic procedure is helpful to detect subtle
lesions in the bronchus which can hardly be
recognized by conventional bronchoscopy [8,9].
Lam and associates reported the result of a multi-
center clinical trial in which 173 patients were
enrolled. The relative sensitivity of white light with
LIFE vs white light alone was 6.3 for intraepithelial
lesions. The positive predictive value was 0.33 and
0.39 and the negative predictive value was 0.89 and
0.83 [13]. In the present study, the sensitivity of
conventional bronchoscopy for dysplasia was 51%
and that of the LIFE system was 90%. The positive
predictive value for dysplasia or cancer by conven-
tional bronchoscopy was 64% and that by the LIFE
system was 73%.
Since invasive cancer is usually visible, the aim of
fluorescence diagnosis is not to localize invasive
cancer but to detect early lesions which could not
be observed by conventional bronchoscopy. We
detected 12 early cancer in this study, all of which
could be observed under conventional bronchos-
copy as well. At this stage, to observe the extent of
tumor is one goal of the LIFE system in cancer
management. The LIFE system, when used as an
adjunct to standard bronchoscopy, is a powerful
device to detect dysplastic lesions. A total of 42
subjects with abnormal sputum cytology findings
were enrolled in this study. Localization was
successful in 24 cases (57%, 12 early cancer and 12
dysplasia) by conventional bronchoscopy and in 30
cases (71%, 12 early cancer and 18 dysplasia) by the
LIFE system. Dysplastic lesions were detected in
18% of invasive cancer cases, 33% in CIS cases,
24% in post-operative cases and7% in smokers with
symptoms.
We postulated that the phenomenon of a high
frequency of dysplasia in cancer cases is related to
field cancerization, therefore cases with dysplasia
should be periodically followedup as high risk cases.
Auerbach and co-workers reported in their autopsy
study that CIS was found in 15% of the subjects.
Also they reported CIS was found in 4.4-11.4% in
smokers [14]. As lung cancer patients tend to have
synchronous or metachronous double cancer, endo-
scopic examination may be necessary even for cases
which received operation for peripheral type adeno-
carcinoma.
The specificity of conventional bronchoscopy
was 62% and that of the LIFE system was 66%.
False positive cases in conventional bronchoscopy
were mainly due to thickened bifurcations with
normal mucosa and the reasons for false positive
results with the LIFE system was mainly due to
chronic inflammatory findings (reserve cell hyper-
plasia, thickened basement membrane) which
showed cold spots under fluorescence imaging.
The reason for suspicious LIFE findings in areas
with normal histology is unknown. Molecular
genetic changes such as cumulative gene losses
during the progression ofprecancerous lesions have
been reported [15]. The fluorescence image may
reflect some molecular events which are not
observed microscopically.
Fluorescence studies are spreading throughout
the world, but some problems remain. It is known
that there will be some disagreement concerning the
diagnosis among pathologists particularly when the
specimen is very small. Since it is impossible to
distinguish carcinoma in situ from dysplasia using
the LIFE system, the histopathology of biopsies is
the gold standard. To evaluate the effectiveness of
fluorescence studies, more detailed and objective90 N. IKEDA et al.
criteria of histopathology of different degrees
of dysplasia and carcinoma in situ should be
established.
Due to increasing numbers in early cancers as well
as more elderly patients, minimally invasive treat-
ment is required to maintain quality of life. As
previously reported, surgery can be avoided in some
of the in situ and early cancer when treated by
photodynamic therapy [16,17] while chemopreven-
tion might reverse dysplasia to normal status [18].
At present it has been confirmed that fluorescence
examination can be effective to increase the rate of
detection of early lesions which can be treated by
endoscopic treatment.
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